Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300000, People's Republic of China.
Eur Arch Otorhinolaryngol. 2022 Feb;279(2):567-576. doi: 10.1007/s00405-021-06918-y. Epub 2021 Jun 5.
Oligometastatic nasopharyngeal carcinoma (NPC) is a distinctive subset of metastatic NPC. Imaging examinations and biomarkers can screen out NPC patients with limited number of sites showing metastasis. Past studies have demonstrated the survival advantages of oligometastatic NPC over multiple metastatic NPC. The treatment strategies of de-novo oligometastatic NPC differ owing to the heterogeneity of this disease. This study aims to systematically review the characteristics and treatments of oligometastatic NPC.
PubMed, EMBASE, the Web of Science, and the Cochrane Library were used to search for publications with an emphasis on oligometastatic NPC.
We have presented the current advances on the management of oligometastatic NPC, including the definition, diagnosis, biomarkers, classification, prognosis, subtype, especially systematic therapy, locoregional radiotherapy to the primary tumor, and treatments of the metastatic lesions.
More well-designed prospective clinical trials that are exclusive for oligometastatic NPC are warranted to determine the best treatment paradigm.
寡转移鼻咽癌(NPC)是转移性 NPC 的一个独特亚型。影像学检查和生物标志物可筛选出转移部位有限的 NPC 患者。过去的研究表明,寡转移 NPC 比多转移 NPC 具有生存优势。由于该病的异质性,初治寡转移 NPC 的治疗策略有所不同。本研究旨在系统地回顾寡转移 NPC 的特征和治疗方法。
我们重点检索了 PubMed、EMBASE、Web of Science 和 Cochrane Library 中的相关文献。
我们介绍了寡转移 NPC 管理方面的最新进展,包括定义、诊断、生物标志物、分类、预后、亚型,特别是系统治疗、局部区域放疗原发肿瘤和转移灶的治疗。
需要设计更多专门针对寡转移 NPC 的前瞻性临床试验,以确定最佳的治疗方案。